These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 38596238)

  • 21. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
    Calabresi P; Mechelli A; Natale G; Volpicelli-Daley L; Di Lazzaro G; Ghiglieri V
    Cell Death Dis; 2023 Mar; 14(3):176. PubMed ID: 36859484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroprotective treatment of idiopathic, genetic and atypical Parkinson's disease with alpha-synuclein-Pathology].
    Levin J; Nübling G; Giese A; Janzen A; Oertel W
    Nervenarzt; 2021 Dec; 92(12):1249-1259. PubMed ID: 34735584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein Strains and Their Relevance to Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies.
    Graves NJ; Gambin Y; Sierecki E
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The promise of amplification assays for accurate early detection of α-synucleinopathies: A review.
    Kurapova R; Chouliaras L; O'Brien JT
    Exp Gerontol; 2022 Aug; 165():111842. PubMed ID: 35623540
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia.
    Dorion MF; Yaqubi M; Senkevich K; Kieran NW; MacDonald A; Chen CXQ; Luo W; Wallis A; Shlaifer I; Hall JA; Dudley RWR; Glass IA; ; Stratton JA; Fon EA; Bartels T; Antel JP; Gan-Or Z; Durcan TM; Healy LM
    Brain; 2024 Feb; 147(2):427-443. PubMed ID: 37671615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M
    Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.
    Upcott M; Chaprov KD; Buchman VL
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease.
    Piper DA; Sastre D; Schüle B
    Front Neurosci; 2018; 12():199. PubMed ID: 29686602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies.
    Gámez-Valero A; Beyer K
    Genes (Basel); 2018 Jan; 9(2):. PubMed ID: 29370097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies.
    Hart de Ruyter FJ; Morrema THJ; den Haan J; Gase G; Twisk JWR; de Boer JF; Scheltens P; Bouwman FH; Verbraak FD; Rozemuller AJM; Hoozemans JJM
    NPJ Parkinsons Dis; 2023 Aug; 9(1):124. PubMed ID: 37640753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of autophagic protein DEF8 in Lewy bodies.
    Tanaka MT; Miki Y; Bettencourt C; Ozaki T; Tanji K; Mori F; Kakita A; Wakabayashi K
    Biochem Biophys Res Commun; 2022 Oct; 623():170-175. PubMed ID: 35921708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synucleinopathies: Where we are and where we need to go.
    Brás IC; Dominguez-Meijide A; Gerhardt E; Koss D; Lázaro DF; Santos PI; Vasili E; Xylaki M; Outeiro TF
    J Neurochem; 2020 May; 153(4):433-454. PubMed ID: 31957016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
    Rosborough K; Patel N; Kalia LV
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases.
    So RWL; Watts JC
    J Mol Biol; 2023 Jun; 435(12):168011. PubMed ID: 36792008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.